Jump to content

Nicholas P. Restifo

Edit links
From Wikipedia, the free encyclopedia
Nicholas P. Restifo
Born (1960-07-24) 24 July 1960 (age 64)
Columbus, Ohio
NationalityAmerican
EducationJohns Hopkins University,
New York University School of Medicine
OccupationImmunologist
Known forT cell-based immunotherapy

Nicholas P. Restifo (born July 24, 1960) is an American immunologist, physician and educator in cancer immunotherapy. Until July 2019, he was a tenured senior investigator in the intramural National Cancer Institute of the National Institutes of Health at Bethesda, Maryland.[1][self-published source?] Nicholas was an executive vice president of research at Lyell based in San Francisco.

Restifo has been a pioneer in the use of T cell-based immunotherapy.

Early life and education

[edit]

Restifo was born July 24, 1960, in Columbus, Ohio. He grew up in a small town, Amherst, Ohio, and went to high school in Lorain, Ohio. He completed his undergraduate education with honors at the Johns Hopkins University and obtained his medical degree from New York University School of Medicine. He first joined the National Cancer Institute, NIH in Bethesda, Maryland in 1989. He was recruited from the Memorial Sloan Kettering Cancer Center, where he worked in the laboratory of Murray Brennan, the former chairman of Surgery. He became a principal investigator[2] in 1993 and has authored or co-authored more than 350 papers and book chapters on cancer immunotherapy.[3] His h-index is 156 and his work has been cited more than 104,000 times according to Google Scholar.[4]

Research

[edit]

Restifo is a pioneer in the field of cancer immunotherapy with a focus on the use of T cells in the treatment of malignancy.[5] One of Dr. Restifo's major discoveries is that CD8+ T cells experience a stereotypical maturational program.[6] His early work was focused on discovering how tumor cells can escape from T cell recognition.[7][8] He went on to characterize the mechanisms underlying why T cells survive and expand better after lymphodepletion.[9] His most recent efforts include a focus on how elements – literally from the periodic table – influence cancer immunity. These include work on how oxygen can inhibit anti-tumor immunity [10] and how potassium ions from dying cancer cells can shut down the anti-tumor response.[11]

Successful treatment of patients with cancer is the goal of his laboratory, and his therapeutic approaches employ adoptive T cell transfer, gene modification and cellular reprogramming.[12] Basic aspects of tumor and T cell immunology inform novel therapeutic interventions in the clinic.

Restifo and his research team have made contributions to the fields of adoptive cell transfer[12] tumor immune-escape,[13][14] virally encoded cancer vaccines,[15] adoptive cell transfer for the treatment of cancer, and the biology of self/tumor-reactive T cells, with an emphasis on memory CD8+ T cells.[16]

Awards

[edit]

Solomon A. Berson Prize for Clinical and Translational Science, 2017 Clarivate Analytics, “World’s Most Influential Scientific Minds” Double Citation in Immunology and Clinical Medicine 2014 (Thomson Reuters) NIH Director’s Award, 2017, Federal Technology Transfer Award, 2017 Primary Organizer of four Keystone Symposia and three International Cancer Immunotherapy Meetings at NIH. Plenary and Keynote Invited talks at AACR, SITC, ASH, ASCGT, AAI and other meetings.

Academic Appointments, primary mentor for PhD students: 2014 Cambridge University, UK; 2011 U of Pennsylvania School of Medicine; 2010 Georgetown U School of Medicine; 2009 George Wash U School of Medicine.

See also

[edit]

References

[edit]
  1. ^ "Nicholas P. Restifo, M.D." National Cancer Institute. September 12, 2009. Archived from the original on March 24, 2010. Retrieved April 14, 2010.
  2. ^ "Nicholas P. Restifo, M.D. | Center for Cancer Research". ccr.cancer.gov. Archived from the original on 2015-09-12.
  3. ^ Search Results for author Restifo NP on PubMed.
  4. ^ "Nicholas P Restifo, MD".
  5. ^ Rosenberg, Steven A.; Restifo, Nicholas P. (2015). "Adoptive cell transfer as personalized immunotherapy for human cancer". Science. 348 (6230): 62–68. Bibcode:2015Sci...348...62R. doi:10.1126/science.aaa4967. PMC 6295668. PMID 25838374.
  6. ^ Gattinoni, L., Lugli, E., Ji, Y. et al. A human memory T cell subset with stem cell–like properties. Nat Med 17, 1290–1297 (2011). https://doi.org/10.1038/nm.2446
  7. ^ Nicholas P. Restifo, Francesco M. Marincola, Yutaka Kawakami, Jeff Taubenberger, John R. Yannelli, Steven A. Rosenberg, Loss of Functional Beta 2 -Microglobulin in Metastatic Melanomas From Five Patients Receiving Immunotherapy , JNCI: Journal of the National Cancer Institute, Volume 88, Issue 2, 17 January 1996, Pages 100–108, https://doi.org/10.1093/jnci/88.2.100
  8. ^ Identification of Human Cancers Deficient in Antigen Processing
  9. ^ DOI:https://doi.org/10.1016/j.it.2004.12.003
  10. ^ Clever, D, et al. (Aug 25, 2016). "Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche". Cell. 166 (5): 1117–1131. doi:10.1016/j.cell.2016.07.032. PMC 5548538. PMID 27565342.
  11. ^ Eil, R, et al. Ionic immune suppression within the tumour microenvironment limits T cell effector function. Nature. 2016 Sep 14. doi: 10.1038/nature19364. [Epub ahead of print]
  12. ^ a b Restifo NP, Dudley ME, Rosenberg SA (March 2012). "Adoptive immunotherapy for cancer: harnessing the T cell response". Nature Reviews Immunology. 12 (4): 269–81. doi:10.1038/nri3191. PMC 6292222. PMID 22437939.
  13. ^ Restifo NP, Esquivel F, Kawakami Y, et al. (February 1993). "Identification of human cancers deficient in antigen processing". The Journal of Experimental Medicine. 177 (2): 265–72. doi:10.1084/jem.177.2.265. PMC 1950463. PMID 8426105.
  14. ^ Khong HT, Restifo NP (November 2002). "Natural selection of tumor variants in the generation of "tumor escape" phenotypes". Nature Immunology. 3 (11): 999–1005. doi:10.1038/ni1102-999. PMC 1508168. PMID 12407407.
  15. ^ Irvine KR, McCabe BJ, Rosenberg SA, Restifo NP (May 1995). "Synthetic Oligonucleotide Expressed by a Recombinant Vaccinia Virus Elicits Therapeutic CTL". Journal of Immunology. 154 (9): 4651–7. doi:10.4049/jimmunol.154.9.4651. PMC 1976247. PMID 7722317.
  16. ^ Gattinoni, Luca; Zhong, Xiao-Song; Palmer, Douglas C.; Ji, Yun; Hinrichs, Christian S.; Yu, Zhiya; Wrzesinski, Claudia; Boni, Andrea; Cassard, Lydie; Garvin, Lindsay M.; Paulos, Chrystal M.; Muranski, Pawel; Restifo, Nicholas P. (July 29, 2009). "Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells". Nature Medicine. 15 (7): 808–813. doi:10.1038/nm.1982. PMC 2707501. PMID 19525962.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Nicholas_P._Restifo&oldid=1217699452"